Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Citation: 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Active as of 2024-12-19

Generated Narrative: Citation 179616

version: 9; Last updated: 2024-11-22 19:27:42+0000

Profile: JournalArticleCitation

url: Citation 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

identifier: FEvIR Object Identifier/https://fevir.net/FOI/179616, https://pubmed.ncbi.nlm.nih.gov/26244877, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.17

version: 2.0.0-ballot

title: 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

status: Active

date: 2024-12-19 14:29:51+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

-CodeValue[x]
*Citation Classification Type fevir-platform-use: FEvIR Platform UseMedline Base

jurisdiction: World

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

approvalDate: 2015-08-25

lastReviewDate: 2024-08-05

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification

type: Citation Source

classifier: MEDLINE

classification

type: MEDLINE Citation Owner

classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish

statusDate

activity: PubMed Pubstatus of Entrez

period: ?? --> 2015-08-06 06:00:00+0000

statusDate

activity: PubMed Pubstatus of Pubmed

period: ?? --> 2015-08-06 06:00:00+0000

statusDate

activity: PubMed Pubstatus of Medline

period: ?? --> 2015-08-26 06:00:00+0000

statusDate

activity: PubMed Pubstatus of PMC release

period: ?? --> 2016-02-20

citedArtifact

identifier: https://pubmed.ncbi.nlm.nih.gov/26244877, mid/NIHMS719565, https://www.ncbi.nlm.nih.gov/pmc//PMC4562797, https://doi.org/10.1056/NEJMoa1503747

relatedIdentifier: https://clinicaltrials.gov/NCT00309985

Titles

-TypeLanguageText
*Primary titleEnglish

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Abstracts

-Text
*

BACKGROUND: Androgen-deprivation therapy (ADT) has been the backbone of treatment for metastatic prostate cancer since the 1940s. We assessed whether concomitant treatment with ADT plus docetaxel would result in longer overall survival than that with ADT alone. METHODS: We assigned men with metastatic, hormone-sensitive prostate cancer to receive either ADT plus docetaxel (at a dose of 75 mg per square meter of body-surface area every 3 weeks for six cycles) or ADT alone. The primary objective was to test the hypothesis that the median overall survival would be 33.3% longer among patients receiving docetaxel added to ADT early during therapy than among patients receiving ADT alone. RESULTS: A total of 790 patients (median age, 63 years) underwent randomization. After a median follow-up of 28.9 months, the median overall survival was 13.6 months longer with ADT plus docetaxel (combination therapy) than with ADT alone (57.6 months vs. 44.0 months; hazard ratio for death in the combination group, 0.61; 95% confidence interval [CI], 0.47 to 0.80; P<0.001). The median time to biochemical, symptomatic, or radiographic progression was 20.2 months in the combination group, as compared with 11.7 months in the ADT-alone group (hazard ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). The rate of a prostate-specific antigen level of less than 0.2 ng per milliliter at 12 months was 27.7% in the combination group versus 16.8% in the ADT-alone group (P<0.001). In the combination group, the rate of grade 3 or 4 febrile neutropenia was 6.2%, the rate of grade 3 or 4 infection with neutropenia was 2.3%, and the rate of grade 3 sensory neuropathy and of grade 3 motor neuropathy was 0.5%. CONCLUSIONS: Six cycles of docetaxel at the beginning of ADT for metastatic prostate cancer resulted in significantly longer overall survival than that with ADT alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00309985.).

relatesTo

type: cites

classifier: Journal Article

citation:

Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/0/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/0

relatesTo

type: cites

classifier: Journal Article

citation:

Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355:1491–8.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/10801170/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/10801170

relatesTo

type: cites

classifier: Journal Article

citation:

Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002;95:361–76.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/12124837/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/12124837

relatesTo

type: cites

classifier: Journal Article

citation:

Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368:1314–25.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/23550669/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23550669

relatesTo

type: cites

classifier: Journal Article

citation:

Tangen CM, Hussain MH, Higano CS, et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346) J Urol. 2012;188:1164–9.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/22921015/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/22921015

relatesTo

type: cites

classifier: Journal Article

citation:

Wu JN, Fish KM, Evans CP, Devere White RW, Dall’Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014;120:818–23.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/24258693/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/24258693

relatesTo

type: cites

classifier: Journal Article

citation:

Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/15470214/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/15470214

relatesTo

type: cites

classifier: Journal Article

citation:

Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/15470213/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/15470213

relatesTo

type: cites

classifier: Journal Article

citation:

Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol. 2008;26:5936–42.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/19029421/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/19029421

relatesTo

type: cites

classifier: Journal Article

citation:

Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149–58.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/23306100/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23306100

relatesTo

type: cites

classifier: Journal Article

citation:

Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419–24.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/2503724/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/2503724

relatesTo

type: cites

classifier: Journal Article

citation:

Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036–42.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/9761805/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/9761805

relatesTo

type: cites

classifier: Journal Article

citation:

Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst. 2000;92:205–16.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/10655437/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/10655437

relatesTo

type: cites

citation:

Jennison CTB. Statistical approaches to interim monitoring of medical trials: a review and commentary. Stat Sci. 1990;5:299–317.

relatesTo

type: cites

citation:

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.

relatesTo

type: cites

citation:

Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187–220.

relatesTo

type: cites

classifier: Journal Article

citation:

Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/5910392/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/5910392

relatesTo

type: cites

citation:

Cox D. Analysis of binary data. London: Methuen and Co; 1970.

relatesTo

type: cites

classifier: Journal Article

citation:

de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/21612468/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/21612468

relatesTo

type: cites

classifier: Journal Article

citation:

Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/23228172/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23228172

relatesTo

type: cites

classifier: Journal Article

citation:

Beer TM, strong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/24881730/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/24881730

relatesTo

type: cites

classifier: Journal Article

citation:

Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/22894553/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/22894553

relatesTo

type: cites

classifier: Journal Article

citation:

Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/20818862/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/20818862

relatesTo

type: cites

classifier: Journal Article

citation:

de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/20888992/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/20888992

relatesTo

type: cites

classifier: Journal Article

citation:

Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/23863050/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23863050

relatesTo

type: cites

classifier: Journal Article

citation:

James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control of the STAMPEDE trial (MRC PR08, CRUK/06/019) Eur Urol. 2015;67:1028–38.

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/25301760/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/25301760

relatesTo

type: comment-in

classifier: Comment

citation:

BMJ. 2015 Aug 05;351:h4253. doi: 10.1136/bmj.h4253

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/26251343/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26251343

relatesTo

type: comment-in

classifier: Comment

citation:

Nat Rev Clin Oncol. 2015 Oct;12(10):563. doi: 10.1038/nrclinonc.2015.145

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/26305034/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26305034

relatesTo

type: comment-in

classifier: Comment

citation:

Nat Rev Urol. 2015 Dec;12(12):656-8. doi: 10.1038/nrurol.2015.255

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/26526753/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26526753

relatesTo

type: comment-in

classifier: Comment

citation:

Nat Rev Clin Oncol. 2015 Dec;12(12):687-8. doi: 10.1038/nrclinonc.2015.192

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/26552950/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26552950

relatesTo

type: comment-in

classifier: Comment

citation:

BMC Med. 2015 Dec 22;13:304. doi: 10.1186/s12916-015-0543-9

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/26695172/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26695172

relatesTo

type: comment-in

classifier: Comment

citation:

J Urol. 2016 Jan;195(1):94. doi: 10.1016/j.juro.2015.10.055

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/26699961/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26699961

relatesTo

type: comment-in

classifier: Comment

citation:

N Engl J Med. 2016 Jan 21;374(3):287. doi: 10.1056/NEJMc1511800

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/26789883/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26789883

relatesTo

type: comment-in

classifier: Comment

citation:

N Engl J Med. 2016 Jan 21;374(3):286. doi: 10.1056/NEJMc1511800

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/26789884/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26789884

relatesTo

type: comment-in

classifier: Comment

citation:

Eur Urol. 2016 Mar;69(3):540. doi: 10.1016/j.eururo.2015.12.027

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/26867727/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26867727

relatesTo

type: comment-in

classifier: Comment

citation:

Eur Urol. 2016 Apr;69(4):755-6. doi: 10.1016/j.eururo.2016.01.020

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/26972499/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26972499

relatesTo

type: comment-in

classifier: Comment

citation:

Eur Urol. 2016 Jan;69(1):178. doi: 10.1016/j.eururo.2015.10.037

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/27099882/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/27099882

relatesTo

type: comment-in

classifier: Comment

citation:

Urol Oncol. 2017 Mar;35(3):123. doi: 10.1016/j.urolonc.2016.12.021

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/28159490/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/28159490

publicationForm

publishedIn

type: Periodical

identifier: Electronic ISSN Type/1533-4406, ISOAbbreviation/N Engl J Med, ISSN Linking/0028-4793, Medline Title Abbreviation/N Engl J Med, NLM Unique ID/0255562

title: The New England journal of medicine

publisherLocation: United States

citedMedium: Internet

volume: 373

issue: 8

articleDate: 2015-08-20

publicationDateText: 2015-Aug-20

language: English

pageString: 737-46

publicationForm

citedMedium: Internet without issue

articleDate: 2015-08-05

webLocation

classifier: Abstract

url: https://pubmed.ncbi.nlm.nih.gov/26244877/

webLocation

classifier: DOI Based

url: https://doi.org/10.1056/NEJMoa1503747

classification

type: Publishing Model

classifier: Print Electronic

classification

type: Chemical

classifier: Androgen Antagonists, Antineoplastic Agents, Taxoids, Docetaxel, Prostate-Specific Antigen

classification

type: MeSH heading

artifactAssessment: ArtifactAssessment: artifact[x] = this resource

classification

type: Publication type

classifier: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

classification

type: Knowledge Artifact Type

classifier: Journal Article

artifactAssessment: Classifier added by Computable Publishing LLC

classification

type: Citation subset

classifier: IM

contributorship

complete: true

entry

contributor: Sweeney CJ

forenameInitials: CJ

affiliation: From the Department of Medicine (C.J.S.) and the Department of Biostatistics and Computational Biology (Y.-H.C.), Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston (C.J.S.); Johns Hopkins University, Baltimore (M.C., M.E.); University of Wisconsin Carbone Cancer Center (G.L., D.F.J.) and School of Medicine and Public Health (D.F.J.), Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia (Y.-N.W.); Indiana University Melvin and Bren Simon Cancer Center, Indianapolis (N.H.); Mayo Clinic, Rochester, MN (M.K.); University Hospitals Case Medical Center, Seidman Cancer Center (M.M.C.), and Cleveland Clinic Taussig Cancer Institute (J.A.G.) - both in Cleveland; University of Virginia Cancer Center, Charlottesville (R.D.); Comprehensive Cancer Centers of Nevada, Las Vegas (N.J.V.); Siteman Cancer Center, Washington University School of Medicine, St. Louis (J.P.); NorthShore University HealthSystem, Evanston, IL (D.S.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.H.); and Rutgers Cancer Institute of New Jersey, New Brunswick (R.S.D.).

entry

contributor: Chen YH

forenameInitials: YH

entry

contributor: Carducci M

forenameInitials: M

entry

contributor: Liu G

forenameInitials: G

entry

contributor: Jarrard DF

forenameInitials: DF

entry

contributor: Eisenberger M

forenameInitials: M

entry

contributor: Wong YN

forenameInitials: YN

entry

contributor: Hahn N

forenameInitials: N

entry

contributor: Kohli M

forenameInitials: M

entry

contributor: Cooney MM

forenameInitials: MM

entry

contributor: Dreicer R

forenameInitials: R

entry

contributor: Vogelzang NJ

forenameInitials: NJ

entry

contributor: Picus J

forenameInitials: J

entry

contributor: Shevrin D

forenameInitials: D

entry

contributor: Hussain M

forenameInitials: M

entry

contributor: Garcia JA

forenameInitials: JA

entry

contributor: DiPaola RS

forenameInitials: RS

Generated Narrative: Practitioner #contributor0

name: Christopher J Sweeney

Generated Narrative: Practitioner #contributor1

name: Yu-Hui Chen

Generated Narrative: Practitioner #contributor2

name: Michael Carducci

Generated Narrative: Practitioner #contributor3

name: Glenn Liu

Generated Narrative: Practitioner #contributor4

name: David F Jarrard

Generated Narrative: Practitioner #contributor5

name: Mario Eisenberger

Generated Narrative: Practitioner #contributor6

name: Yu-Ning Wong

Generated Narrative: Practitioner #contributor7

name: Noah Hahn

Generated Narrative: Practitioner #contributor8

name: Manish Kohli

Generated Narrative: Practitioner #contributor9

name: Matthew M Cooney

Generated Narrative: Practitioner #contributor10

name: Robert Dreicer

Generated Narrative: Practitioner #contributor11

name: Nicholas J Vogelzang

Generated Narrative: Practitioner #contributor12

name: Joel Picus

Generated Narrative: Practitioner #contributor13

name: Daniel Shevrin

Generated Narrative: Practitioner #contributor14

name: Maha Hussain

Generated Narrative: Practitioner #contributor15

name: Jorge A Garcia

Generated Narrative: Practitioner #contributor16

name: Robert S DiPaola

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

content

type: components (if present) include qualifier codings

classifier: Adult

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Aged

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Aged, 80 and over

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Androgen Antagonists

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: adverse effects

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: therapeutic use

Components

-TypeClassifier
*is Major topicYes

content

type: components (if present) include qualifier codings

classifier: Antineoplastic Agents

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: adverse effects

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: therapeutic use

Components

-TypeClassifier
*is Major topicYes

content

type: components (if present) include qualifier codings

classifier: Docetaxel

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Drug Therapy, Combination

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Follow-Up Studies

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Humans

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Kaplan-Meier Estimate

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Male

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Middle Aged

freeToShare: true

Components

-TypeClassifier
*qualifieris not a major topic

content

type: components (if present) include qualifier codings

classifier: Neutropenia

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: chemically induced

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: epidemiology

Components

-TypeClassifier
*is Major topicNo

content

type: components (if present) include qualifier codings

classifier: Prostate-Specific Antigen

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: blood

Components

-TypeClassifier
*is Major topicNo

content

type: components (if present) include qualifier codings

classifier: Prostatic Neoplasms

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: drug therapy

Components

-TypeClassifier
*is Major topicYes

component

type: qualifier

classifier: mortality

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: pathology

Components

-TypeClassifier
*is Major topicNo

content

type: components (if present) include qualifier codings

classifier: Taxoids

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: adverse effects

Components

-TypeClassifier
*is Major topicNo

component

type: qualifier

classifier: therapeutic use

Components

-TypeClassifier
*is Major topicYes